Cargando…
Recombinant Human Insulin-Like Growth Factor-1 Treatment: Prime Time or Timeout? [Commentary on “Recombinant Human Insulin Like Growth Factor-1 Treatment: Ready for Prime Time” by Bright GM, Mendoza JR, Rosenfeld RG, Endocrinol Metab Clin N Am 2009; 38:625–38]
Autor principal: | Rosenbloom, Arlan L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821650/ https://www.ncbi.nlm.nih.gov/pubmed/20169131 http://dx.doi.org/10.1155/2009/429684 |
Ejemplares similares
-
Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia - reply to the letter from Cohen, Peehl and Rosenfeld
por: Mantzoros, CS, et al.
Publicado: (1998) -
Mr Heitler and L Rosenfeld
por: Unknown
Publicado: (2002) -
Selected papers of Léon Rosenfeld
por: Stachel, John J, et al.
Publicado: (1979) -
Insulin-Like Growth Factor 1 in the Preterm Rabbit Pup: Characterization of Cerebrovascular Maturation following Administration of Recombinant Human Insulin-Like Growth Factor 1/Insulin-Like Growth Factor 1-Binding Protein 3
por: Gram, Magnus, et al.
Publicado: (2021) -
Recombinant insulin-like growth factor-1 activates satellite cells in the mouse urethral rhabdosphincter
por: Wei, Wenjie, et al.
Publicado: (2013)